Clinical Trial Update: GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating GEMOX (gemcitabine + oxaliplatin) in combination with donafenib and tislelizumab for advanced biliary tract carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Biliary Tract Carcinoma | Phase 2 | Status: RECRUITING